Techedge to Present at C.E Unterberg, Towbin Emerging Growth Conference.ISELIN, N.J. -- Techedge Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :TEDG) announced that it will be presenting at C.E Unterberg, Towbin Emerging Growth Conference to be held on July 11 and 12 at the Mandarin Oriental Hotel in New York city New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Dr. Jean-Denis Shu (MD, MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration ), the CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Chief Scientist of its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. China BioPharma Limited, stated, "it is a great opportunity for us to present to investors of our technology, products and marketing, as well as China BioPharma's objective, strategy, business model, and ongoing initiatives." The presentation will include an interactive question and answer session. Following the presentation, Dr. Shu will be available for one-on-one meetings with analysts and investors. Participation or attendance is by invitation only. Clients interested in attending should contact their C.E Unterberg, Towbin representatives. About China BioPharma Limited China BioPharma is a fast growing developer, producer and distributor of bio-pharmaceutical products in China. Through its investment and ownership of leading Chinese bio-pharmaceutical companies, the Company's current products consist of human vaccines for influenza and epidemic hemorrhagic fever epidemic hemorrhagic fever n. An acute viral hemorrhagic fever characterized by headache, high fever, sweating, thirst, photophobia, coryza, cough, myalgia, arthralgia, and abdominal pain with nausea and vomiting. (HFV HFV High-frequency ventilation ) with high reputation and market shares among Chinese made vaccines. With a fast growing market, newly completed production facilities, and several other new vaccines in the pipeline, it is expected to have a steady and significant growth in the next few years. China BioPharma also plans to expand its market beyond China to other developing countries. About Techedge Inc. Techedge Inc. has recently repositioned itself to focus at opportunities in the fast growing bio-pharmaceutical sector in China. For more information, please visit its website at www.techedgeinc.net FORWARD-LOOKING STATEMENT DISCLAIMER Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion